Atea Pharma reported a Q4 net loss of USD 44.9 million and a FY net loss of USD 158.3 million. Q4 R&D expenses were USD 47.8 million (+86.2%) and FY R&D expenses were USD 148.0 million (+2.7%), while Q4 G&A expenses were USD 7.1 million (-46.7%) and FY G&A expenses were USD 32.9 million (-32.7%). Q4 loss from operations was USD 54.9 million (+40.8%) and FY loss from operations was USD 180.9 million (-6.3%); Q4 interest income and other, net was USD 3.3 million (-42.2%) and FY interest income and other, net was USD 16.4 million (-35.8%). Cash, cash equivalents and marketable securities totaled USD 301.8 million at Dec. 31, 2025 (-33.6%). On the business front, Atea said it completed enrollment in its North American Phase 3 C-BEYOND trial of the bemnifosbuvir/ruzasvir fixed-dose combination for chronic HCV in December 2025 with over 880 patients, with topline results expected mid-2026; the ex-North America Phase 3 C-FORWARD trial is expected to complete enrollment mid-2026 with topline results anticipated around year-end 2026. The company also expanded into hepatitis E, naming AT-587 as its lead candidate and expecting it to enter the clinic in mid-2026, and highlighted in vitro data presented at CROI 2026 showing AT-587 and AT-2490 were 30-150-fold more potent against HEV than sofosbuvir and ribavirin.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603051605PRIMZONEFULLFEED9666780) on March 05, 2026, and is solely responsible for the information contained therein.
Comments